BTG receives not-approvable letter from the US FDA for ELEVAIR™
BTG plc (LSE: BTG), the global specialist healthcare company, today announces that PneumRx® has received confirmation from the US Food and Drug Administration (FDA) that the Premarket Approval (PMA) application for its ELEVAIR™ Endobronchial Coil System for the treatment of people with severe emphysema is not approvable. This follows the FDA Advisory Panel’s recommendation in June 2018 not to approve ELEVAIR™.
BTG is reviewing options and will provide an update in due course.
For further information contact:
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
BTG is a global healthcare company focused on Interventional Medicine. Our innovative medical technology helps physicians treat their patients through minimally invasive procedures. We have a growing portfolio of products that advance the treatment of cancer, vascular conditions and severe emphysema. BTG's Pharmaceuticals business provides products that help patients overexposed to certain medications or toxins. To learn more about BTG, please visit: btgplc.com.
Back to press releases